Global Dermatophytic Onychomycosis Treatment Market Size Study & Forecast, by Product Type (Tablets, Nail Paints), By Route of Administration (Oral, Topical), By Type (Prescribed, Over-the-Counter (OTC)), By Distribution Channel (Hospital Pharmacies, Reta

Global Dermatophytic Onychomycosis Treatment Market Size Study & Forecast, by Product Type (Tablets, Nail Paints), By Route of Administration (Oral, Topical), By Type (Prescribed, Over-the-Counter (OTC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channels), and Regional Analysis, 2023-2030

Global Dermatophytic Onychomycosis Treatment Market is valued at approximately USD 4.68 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.0% over the forecast period 2023-2030. Dermatophytic onychomycosis, also known as fungal nail infection, is a common condition caused by various types of fungi, primarily dermatophytes. It affects the nails, causing them to become discolored, brittle, and thickened. It constitutes approximately one-third of all fungal infections worldwide, with dermatophytes responsible for around 70%-80% of these cases. This growing prevalence has led to a rising need for medications designed to treat dermatophytic onychomycosis. The growing cases of diabetes, increasing awareness of dermatophytic onychomycosis and its treatment, as well as surging demand for topical treatments are the most prominent factors that are propelling the market demand across the globe.

In addition, the increasing aging population, coupled with the growing prevalence of onychomycosis globally are the leading factors that are accelerating the market growth during the estimated period. According to a 2020 article titled ""High Prevalence of Mixed Infections in Global Onychomycosis,"" the global prevalence of onychomycosis is estimated to be around 10%, with Trichophyton rubrum being the most commonly identified causative organism. Also, as per the NCBI article published in 2022, onychomycosis accounts for roughly half of all nail-related disorders and affects approximately 5.5% of the global population. Furthermore, data from the World Health Organization (WHO) in 2021 indicates that by 2030, approximately one in every six individuals globally will be aged 60 years or older. The number of individuals aged 60 and above is projected to increase from 1 billion in 2020 to 1.4 billion by 2050, effectively doubling the global population of adults aged 60 and over to 2.1 billion by 2050. Moreover, the increasing government support for research and development, as well as the rising introduction of new and innovative treatments presents various lucrative opportunities over the forecast years. However, the high cost of treatment and the side effects of treatment are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Dermatophytic Onychomycosis Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the growing investment in R&D activities, the introduction of generic versions of oral antifungal medications, along with the growing awareness about the impact of fungal nail infections. Whereas, Asia Pacific is expected to grow at the fastest CAGR over the forecast years. The rising healthcare expenditure, increasing prevalence of onychomycosis, and diabetic patient populations are significantly propelling the market demand across the region.

Major market players included in this report are:
Bausch Health Companies Inc.
Pfizer Inc.
Galderma S.A
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc.
Cipla Inc.
Kaken Pharmaceuticals Co., Ltd.
Novan, Inc.
Anacor Pharmaceuticals, Inc.
Moberg Pharma AB

Recent Developments in the Market:
 In July 2021, Kaken Pharmaceutical and Almirall S.A. signed a license and distribution agreement to give Almirall the rights to produce and market the topical antifungal efinaconazole in Europe. The objective of this initiative is to increase the company’s geographic reach in Europe.
 In July 2021, Zydus Lifesciences secured approval from the U.S. FDA to market efinaconazole topical solution for the management of onychomycosis. This regulatory milestone bolstered the company's presence and market position in the United States.
Global Dermatophytic Onychomycosis Treatment Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Product Type, Route of Administration, Type, Distribution Channel, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:
Tablets
Nail Paints

By Route of Administration:
Oral
Topical

By Type:
Prescribed
Over-the-Counter (OTC)

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Channels

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Bausch Health Companies Inc.
Pfizer Inc.
Galderma S.A
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc.
Cipla Inc.
Kaken Pharmaceuticals Co., Ltd.
Novan, Inc.
Anacor Pharmaceuticals, Inc.
Moberg Pharma AB

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.